+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Pharmacokinetic profiles of hydrochlorothiazide alone and in combination with benazepril or valsartan in healthy Chinese volunteers: evaluation of the potential interaction



Pharmacokinetic profiles of hydrochlorothiazide alone and in combination with benazepril or valsartan in healthy Chinese volunteers: evaluation of the potential interaction



International Journal of Clinical Pharmacology and Therapeutics 49(12): 756-764



To compare the pharmacokinetic (PK) profiles and evaluate the PK interaction of hydrochlorothiazide (HCTZ) used alone and in combination with benazepril (BENA) or valsartan (VAL) in healthy Chinese volunteers. Data from two Phase I clinical trials (Study A and Study B) were combined and analyzed. Study A was an open, randomized, three-period crossover study. Eligible healthy male Chinese volunteers were randomly assigned to receive a single dose of the HCTZ (25 mg), BENA (20 mg) or HCTZ/BENA (25/20 mg). Study B was an open randomized, two-period crossover study of VAL/HCTZ (160/12.5 mg) in two formulations. A 7-day washout period was designed between alternate formulations in both studies. Multiple blood samples were collected up to 48 h post-dose, and plasma concentrations of HCTZ were analyzed using high performance liquid chromatography with tandem mass spectrometric detection (HPLC-MS/MS) system. Adverse events (AEs) were monitored and documented throughout the study period. 12 subjects completed Study A and 18 subjects completed Study B. Mean maximum plasma concentration (C(max)) was 168, 121 and 418 ng/ml and mean exposure (AUC(0-48 h)) was 1,160, 955 and 2,801 ng × h/ml following a single dose of HCTZ (25 mg) alone, BENA/HCTZ (20/25 mg) and VAL/HCTZ (160/12.5 mg), respectively. There was significant decrease in C(max) (90% confidence interval: 64.4 - 78.0%) and AUC(0-48 h) (90% confidence interval: 75.9 - 89.5%) of HCTZ with BENA co-administration, whereas concomitant VAL with HCTZ led to significant increase (approximate 1.5-fold) in C(max) and AUC(0-48 h) of plasma HCTZ even without dose normalizing. The apparent terminal half-life (t(1/2)) and the time to C(max) (tmax) were unchanged between the two studies. Overall, HCTZ alone as well as in combination with BENA and VAL was well tolerated within the scope of the current studies in Chinese health volunteers. BENA decreased the bioavailability of HCTZ in Chinese healthy volunteers while VAL greatly increased the concentration of HCTZ in plasma during coadministration. The combination of HCTZ with BENA or VAL was safe and well tolerated.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 054957283

Download citation: RISBibTeXText

PMID: 22122818


Related references

Interaction between benazepril hydrochloride and hydrochlorothiazide in healthy volunteers. European Heart Journal 10(ABSTR Suppl.): 118, 1989

Combination of hydrochlorothiazide or benazepril with valsartan in hypertensive patients unresponsive to valsartan alone. Journal of Hypertension 19(11): 2097-2104, 2001

Pharmacokinetic properties and bioequivalence of two irbesartan/ hydrochlorothiazide fixed-dose combination tablets in healthy male Chinese volunteers. International Journal of Clinical Pharmacology and Therapeutics 53(7): 573-581, 2015

Pharmacokinetic interactions of valsartan and hydrochlorothiazide: an open-label, randomized, 4-period crossover study in healthy Egyptian male volunteers. Clinical Therapeutics 35(6): 846-861, 2013

Lack of pharmacokinetic interactions of aliskiren, a novel direct renin inhibitor for the treatment of hypertension, with the antihypertensives amlodipine, valsartan, hydrochlorothiazide (HCTZ) and ramipril in healthy volunteers. International Journal of Clinical Practice 60(11): 1343-1356, 2006

The absence of a pharmacokinetic interaction between aspirin and the angiotensin-converting enzyme inhibitor benazepril in healthy volunteers. Biopharmaceutics and Drug Disposition 15(6): 451-461, 1994

The absence of a pharmacokinetic interaction between aspirin and the angiotensin-converting enzyme inhibitor benazepril in the healthy volunteers. Biopharmaceutics & Drug Disposition 15(6): 451-461, 1994

Investigation of a potential pharmacokinetic interaction between perindopril arginine and amlodipine when administered as a single perindopril/amlodipine fixed-dose combination tablet in healthy Chinese male volunteers. International Journal of Clinical Pharmacology and Therapeutics 54(1): 43-51, 2016

Evaluation of the cognitive, psychomotor and pharmacokinetic profiles of rupatadine, hydroxyzine and cetirizine, in combination with alcohol, in healthy volunteers. Human Psychopharmacology 21(1): 13-26, 2006

Pharmacokinetic comparison of amlodipine adipate/valsartan fixed-dose combination with amlodipine besylate/valsartan fixed-dose combination in healthy volunteers. International Journal of Clinical Pharmacology and Therapeutics 53(1): 66-74, 2015

Evaluation of the Potential Pharmacokinetic Interaction between Atomoxetine and Fluvoxamine in Healthy Volunteers. Pharmacology 99(1-2): 84-88, 2017

The evaluation of potential pharmacokinetic interaction between sirolimus and tacrolimus in healthy volunteers. European Journal of Clinical Pharmacology 69(4): 835-842, 2013

Evaluation of the potential pharmacokinetic interaction between almotriptan and fluoxetine in healthy volunteers. Journal of Clinical Pharmacology 41(2): 217-223, 2001

Evaluation of the potential pharmacokinetic/pharmacodynamic interaction between fluoxetine and reboxetine in healthy volunteers. Clinical Drug Investigation 18(2): 141-150, 1999

Evaluation of the pharmacokinetic and pharmacodynamic drug interactions between cilnidipine and valsartan, in healthy volunteers. Drug Design Development and Therapy 8: 1781-1788, 2014